IMAC (IMAC) Competitors $0.05 -0.01 (-16.64%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock IMAC vs. KZR, BHG, MODD, SPRO, CELU, CNTB, DTIL, ICCC, LTRN, and RNTXShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Kezar Life Sciences (KZR), Bright Health Group (BHG), Modular Medical (MODD), Spero Therapeutics (SPRO), Celularity (CELU), Connect Biopharma (CNTB), Precision BioSciences (DTIL), ImmuCell (ICCC), Lantern Pharma (LTRN), and Rein Therapeutics (RNTX). These companies are all part of the "medical" sector. IMAC vs. Kezar Life Sciences Bright Health Group Modular Medical Spero Therapeutics Celularity Connect Biopharma Precision BioSciences ImmuCell Lantern Pharma Rein Therapeutics IMAC (NASDAQ:IMAC) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Is IMAC or KZR more profitable? Kezar Life Sciences has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% Kezar Life Sciences N/A -54.95%-46.11% Do analysts recommend IMAC or KZR? Kezar Life Sciences has a consensus price target of $39.50, indicating a potential upside of 702.85%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Kezar Life Sciences is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals believe in IMAC or KZR? 24.3% of IMAC shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 10.0% of IMAC shares are owned by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, IMAC or KZR? IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Which has stronger earnings & valuation, IMAC or KZR? IMAC has higher revenue and earnings than Kezar Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M0.09-$10.54MN/AN/AKezar Life Sciences$7M5.14-$101.87M-$11.55-0.43 Does the MarketBeat Community favor IMAC or KZR? Kezar Life Sciences received 66 more outperform votes than IMAC when rated by MarketBeat users. However, 60.17% of users gave IMAC an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformIMACOutperform Votes7160.17% Underperform Votes4739.83% Kezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% Does the media refer more to IMAC or KZR? In the previous week, Kezar Life Sciences had 2 more articles in the media than IMAC. MarketBeat recorded 12 mentions for Kezar Life Sciences and 10 mentions for IMAC. Kezar Life Sciences' average media sentiment score of 0.26 beat IMAC's score of 0.20 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Kezar Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKezar Life Sciences beats IMAC on 10 of the 16 factors compared between the two stocks. Remove Ads Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38M$1.09M$5.63B$7.84BDividend YieldN/AN/A5.33%4.01%P/E RatioN/AN/A23.5518.73Price / Sales0.090.09388.2390.77Price / CashN/AN/A38.1734.64Price / Book0.080.086.894.23Net Income-$10.54M-$10.54M$3.20B$247.47M7 Day PerformanceN/AN/A-3.06%-2.29%1 Month PerformanceN/AN/A1.51%-5.81%1 Year PerformanceN/AN/A9.37%-0.96% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$0.05-16.6%N/A-98.3%$1.38M$15.22M0.00106News CoverageGap UpKZRKezar Life Sciences4.1133 of 5 stars$6.16+4.6%$39.50+541.2%-45.4%$44.94M$7M-0.4760Earnings ReportShort Interest ↑Analyst RevisionNews CoverageBHGBright Health GroupN/A$5.61+6.5%N/A+5.4%$44.78M$2.76B-0.032,840MODDModular Medical1.6549 of 5 stars$1.10-3.5%N/A-40.5%$44.73MN/A-2.0820SPROSpero Therapeutics4.3071 of 5 stars$0.82-0.6%$5.00+511.6%-55.2%$44.57M$89.87M11.68150Earnings ReportNews CoverageHigh Trading VolumeCELUCelularity0.3224 of 5 stars$1.87+2.7%N/A-66.1%$44.52M$48.20M0.00220Short Interest ↑CNTBConnect Biopharma3.5273 of 5 stars$0.80-1.8%$8.00+900.0%-60.9%$44.20M$24.12M0.00110Short Interest ↓News CoverageGap UpDTILPrecision BioSciences4.3023 of 5 stars$5.64+3.5%$37.67+567.8%-65.3%$43.26M$75.10M94.02200Earnings ReportAnalyst ForecastShort Interest ↓ICCCImmuCell0.7864 of 5 stars$4.78-2.6%N/A-5.5%$42.61M$26.49M-9.5670Short Interest ↓LTRNLantern Pharma0.7387 of 5 stars$3.90+2.1%N/A-59.7%$42.06MN/A-2.1920Earnings ReportNews CoverageRNTXRein TherapeuticsN/A$1.93+1.0%N/AN/A$41.82MN/A-0.629Gap Up Remove Ads Related Companies and Tools Related Companies Kezar Life Sciences Competitors Bright Health Group Competitors Modular Medical Competitors Spero Therapeutics Competitors Celularity Competitors Connect Biopharma Competitors Precision BioSciences Competitors ImmuCell Competitors Lantern Pharma Competitors Rein Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAC) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMAC Stock Free IMAC Stock Alerts